Clinical trials

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.

A randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.

A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.

A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard;dermatologic management on selected dermatologic adverse events among patients with locally;advanced or metastatic EGFR-mutated NSCLC treated first-line with;amivantamab + lazertinib.

68Ga-FAPI-46 PET/CT for predicting histological response;to neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors.

DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI.

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors.

Prospective study of omission of whole-breast radiotherapy following breast-conserving surgery in patients with very low risk ductal carcinoma in situ of the breast